Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;11(4):365-366.
doi: 10.1093/ehjcvp/pvaf020.

Early initiation of SGLT2 inhibitors after acute myocardial infarction

Andeas Hammer  1 , Samuel Sossalla  2   3 , Patrick Sulzgruber  1
Affiliations

Early initiation of SGLT2 inhibitors after acute myocardial infarction

Andeas Hammer et al. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

Keywords: Acute myocardial infarction; Heart failure; NSTEMI; SGLT2 inhibitors; STEMI.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S.S. recieved speakers/consulting honoraria from AstraZeneca, Novartis, Berlin-Chemie, Daiichi Sankyo, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, and Lilly. P.S. reports grants from Daiichi Sankyo and grants and personal fees from Boehringer Ingelheim and grants from AstraZeneca outside the submitted work. A.H. has nothing to disclose.

Figures

Figure 1
Figure 1
Overview of the EMPACT-MI and DAPA-MI trials. Legend: A brief overview of the DAPA-MI and EMPACT-MI trials. Abbreviations: AFIB, atrial fibrillation; CI, confidence interval; DM, diabetes mellitus; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Engström A, Söderling J, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Pasternak B, Ueda, P. Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. Eur Heart J Cardiovasc Pharmacother 2024;10:432–443. - PMC - PubMed
    1. Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, Ferdinandy P, Grove EL, Rocca B, Magavern E, Sulzgruber P, Semb AG, Sossalla S, Niessner A, Kaski JC, Dobrev D. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. Eur Heart J Cardiovasc Pharmacother 2024;10:219–244. - PMC - PubMed
    1. Von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, Moertl D, Auersperg P, Reiter C, Rieder T, Siller-Matula JM, Gager GM, Hasun M, Weidinger F, Pieber TR, Zechner PM, Herrmann M, Zirlik A, Holman RR, Oulhaj A, Sourij H. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J 2022;43:4421–4432. - PMC - PubMed
    1. James S, Erlinge D, Storey RF, Mcguire DK, De Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R, Hoole SP, Jones DA, Lee K, Tygesen H, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E, Deanfield J, Oldgren J. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 2024;3:EVIDoa2300286. - PubMed
    1. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, Van Der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. Empagliflozin after acute myocardial infarction. N Engl J Med 2024;390:1455–1466. - PubMed